Skip to main content
. 2020 Apr 22;122(12):1782–1790. doi: 10.1038/s41416-020-0840-8

Fig. 2. Increased counts of FKBP51s+ Tregs in responder patients to anti-PD1.

Fig. 2

a Total Treg counts and b FKBP51s Treg counts in cases (11, R, and 11, NR) and controls (n = 64). c Graphic representation of FKBP51s Treg counts at baseline and during treatments from 8 R and 8 NR patients. d PFS curves in R and NR patients: median PFS was 2.8 months in NR and not reached in R. e PFS curves according to FKBP51s Treg values, using a threshold of 1%: median PFS was 4.2 months and not reached in patients with <1% or ≥1% of FKBP51s Tregs, respectively. f ROC curve according to FKBP51s Treg values.